Mereo BioPharma Group (MREO) Stock: Buy, Sell, or Hold?
MREO - Mereo BioPharma Group plc American Depositary Shares
$0.38
0.01 (3.52%)
▲
5d:
+2.65%
30d:
+42.14%
90d:
+19.96%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When MREO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MREO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MREO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MREO is currently trading at $0.38, which is considered extended relative to its 30-day fair value range of $0.25 to $0.35.
Technical Outlook: Technically, MREO is in a strong downtrend. Immediate support is located at $0.29, while resistance sits at $0.42. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: MREO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.96 (+415.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MREO is in a strong downtrend. Immediate support is located at $0.29, while resistance sits at $0.42. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: MREO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.96 (+415.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.25 -
$0.35
Company Quality Score
19/100
(STRONG SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range (+8.5% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 415.4% below Wall St target ($1.96)
- WARNING: Composite score 19/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.25 -
$0.35
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.29
Resistance Level
$0.42
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.95
Wall Street Target
$1.96
(+415.4%)
Share & Embed Analysis
Last updated: October 03, 2026 6:33 PM ET
Data refreshes hourly during market hours. Next update: 7:33 PM
Data refreshes hourly during market hours. Next update: 7:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MREO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
